arrow
W

William E. Russell

department of pediatrics
H指数:47
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Type 1 diabetes screening: reframing the debate from paternalism to partnership. Reply to Scaramuzza AE, Iafusco D, Cherubini V [letter] Type 1 diabetes screening: building a clinician–patient partnership for early care of chronic beta cell failure. Reply to Mallone R, Bandini A [letter]

1型糖尿病筛查: 从家长式到伙伴关系的辩论。回复Scaramuzza AE,Iafusco D,Cherubini V [letter] 1型糖尿病筛查: 建立临床医生-患者伙伴关系,以早期护理慢性 β 细胞衰竭。回复Mallone R,Bandini A [信]

2026-01-240
OAAI
Longitudinal Assessment of Pancreas Volume by MRI Predicts Progression to Stage 3 Type 1 Diabetes
2023-12-272
OAAI
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial

阿巴西普延缓1期高危亲属的1型糖尿病进展: 一项随机、双盲、对照试验

2023-03-1531
OAAI
IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes

IL-6受体阻滞剂不会减慢新发1型糖尿病患者的 β 细胞损失

2021-11-0838
OAAI
Multicenter Assessment of the Pancreas in Type 1 Diabetes (MAP-T1D)
2020-06-010
PRE
The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening

在筛查后具有多种自身抗体的个体中,进展为1型糖尿病的风险是高度可变的

2019-11-2571
OAAI
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

有1型糖尿病风险的亲属中的Anti-CD3抗体Teplizumab

2019-08-15648
OAAI
Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data

低剂量抗胸腺细胞球蛋白保留c肽,降低HbA1c,并增加新发1型糖尿病患者常规T细胞比率的调节: 两年临床试验数据

2019-04-09102
OAAI
Low-Dose Anti-Thymocyte Globulin (ATG) Preserves -Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes

低剂量抗胸腺细胞球蛋白 (ATG) 可保护新发1型糖尿病患者的细胞功能并改善HbA1c

2018-07-16120
OAAI